Articles tagged with Chemotherapy
Clinical trials demonstrate improved survival rates for patients with metastatic melanoma using immune therapies nivolumab and pembrolizumab. These treatments target the 'don't attack' protein PDL1 on tumors, allowing the immune system to prime against tumor tissue.
The combination treatment induced objective responses in 67% of patients with small cell lung cancer, including 10% complete responses. Durable responses were observed, with an overall progression-free survival of 4.6 months.
The study found that nivolumab improved median overall survival by 2.4 months and doubled the one-year survival rate compared to chemotherapy. The immunotherapy drug also reduced the risk of dying from lung cancer by 41%.
The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) provides a rational approach to grading the magnitude of clinical benefit of anti-cancer medicines. The scale will be applied to new drugs approved by the EMA, with high-scoring drugs highlighted in the ESMO Clinical Practice Guidelines.
A recent Mayo Clinic study found that combining the targeted drug ibrutinib with standard chemotherapy significantly reduces the risk of death or cancer progression in patients with relapsed CLL or SLL. The treatment results in a nearly 80% reduction in mortality, offering new hope for longer disease control and decreased risk of relapse.
A study has identified a possible new combination chemotherapy regimen for patients with advanced metastatic castrate-resistant prostate cancer. The treatment, combining cabazitaxel and carboplatin, significantly extended progression-free survival by 2.3 months compared to single-agent therapy.
Researchers at MD Anderson Cancer Center have identified a biomarker that may boost the response to chemotherapy in patients with ovarian cancer. The study found that miR-506 was associated with improved responses to chemotherapy drugs cisplatin and olaparib, leading to better overall survival.
A phase 1b study has shown impressive response rates of 60-75% in patients with untreated non-small cell lung cancer treated with chemotherapy and an anti-PD-L1 agent. The combination therapy was well-tolerated, with no unexpected toxicities.
New studies reveal that a vitamin pill can reduce non-melanoma skin cancer risk and docetaxel chemotherapy extends the lives of men with advanced prostate cancers. Additionally, new therapies improve outcomes for children with rare kidney cancers and adults with relapsed multiple myeloma.
Patients with locally advanced esophageal cancer who survive 5 years after surgery are at risk for recurrence, new primary cancers, and chronic pulmonary disease. Continued surveillance is necessary to mitigate these risks, particularly for patients with nodal metastases.
Women with breast cancer who follow a physical exercise program during chemotherapy experience less fatigue, nausea, and pain. The study found that both moderate and low-intensity exercise programs significantly reduced the need for dose adjustments in chemotherapy treatment.
Breast cancer survivors experience chemo-brain, a condition characterized by chronically wandering minds and inability to focus. UBC research reveals that their brains are stuck in a disengaged state, making it difficult for them to concentrate on tasks.
Researchers from Oak Crest Institute of Science have developed a matchstick-sized subdermal implant that delivers potent antiretroviral drugs for up to 40 days, showing promise in stopping the spread of HIV. The implant eliminates adherence issues, a critical factor in HIV prevention.
A study has identified molecular changes that occur in tissue after chemotherapy in ovarian cancer patients. The researchers found that these changes could be potential targets for new, more personalized drugs. The findings have the potential to advance treatments for ovarian cancer.
A common anti-fungal drug, itraconazole, has shown potential in treating metastatic prostate cancer and non-small cell lung cancer. The ReDO project is exploring its use in various cancers, offering a more affordable alternative to existing treatments.
Uninsured cancer patients pay 2-43 times more than Medicare and private insurers for chemotherapy drugs, according to a new study. The study found significant price differences for expensive and inexpensive drugs alike.
Scientists have identified a small RNA molecule called miR-182 that can suppress cancer-causing genes in mice with glioblastoma, a deadly type of brain tumor. The new method uses nanotechnology to deliver the microRNA across the blood-brain barrier, targeting multiple oncogenes at once and increasing cancer cell death.
A new study suggests that fasting combined with a class of cancer-inhibiting drugs can starve colorectal, breast and lung cancer cells, potentially replacing chemotherapy. The research found that this combination is equally effective in killing cancer cells.
Researchers have discovered a way to enhance chemotherapy's impact by inhibiting the cellular quality-control mechanism NMD, which helps breast cancer cells survive. This strategy primes cells for apoptosis and increases cell death rates.
A blood test identified patients with advanced colorectal cancer who could benefit from a more intensive chemotherapy regimen, reducing hair loss and other side effects. The study found that patients with higher counts of circulating tumour cells in their blood responded better to treatment.
Researchers have made progress in understanding the scientific basis for scalp cooling technology, which can help patients retain their hair during chemotherapy. The technology has also been shown to boost immune systems and aid recovery, with happier patients experiencing stronger immune responses.
A study by St. Jude Children's Research Hospital found that measuring residual leukemia cells in patient bone marrow during early weeks of chemotherapy helps identify high-risk patients who need intensive therapy. The technique improved survival rates for young leukemia patients, with 93.5% alive five years after diagnosis.
A phase 3 trial shows that brentuximab vedotin significantly increases progression-free survival in adults with hard-to-treat Hodgkin lymphoma. The drug was found to be well-tolerated, with side effects including peripheral neuropathy and neutropenia.
A protein called MG53 is necessary for the repair of injured kidney cells, according to a study published in Science Translational Medicine. The discovery could lead to new preventive or therapeutic treatments for acute kidney failure, which affects over 30 million Americans.
Researchers have developed nanocarriers that selectively release drugs in lung tumor areas, improving treatment efficacy by 10-25 times compared to traditional methods. This approach also reduces the total dose of medicines, minimizing undesirable effects.
The use of the 21-gene recurrence score assay increased from 1.1% to 10.1% among Medicare beneficiaries diagnosed with breast cancer between 2005 and 2009. The majority of tests were performed in patients with intermediate-risk disease, and rates of chemotherapy remained similar during this period.
Women treated with goserelin during chemotherapy experienced an 8% ovarian failure rate compared to 22% for the control group. Goserelin also improved pregnancy rates by 21% within 5 years post-treatment.
A study published in The New England Journal of Medicine found that adding goserelin to chemotherapy regimens can significantly reduce the risk of early menopause and improve fertility in young breast cancer patients. Women who took goserelin had a higher pregnancy rate and were more likely to deliver healthy babies.
Researchers at TSRI have published two studies showing how ABC transporters like P-gp change shape and react to therapeutic drugs. The findings provide clues for designing better molecules to inhibit or evade multidrug resistance.
Researchers found that patients who received chemotherapy after bladder cancer surgery had improved overall survival rates compared to those who underwent surgery alone. The study analyzed over 5,600 patients and demonstrated a significant reduction in mortality risk.
The study, which analyzed data from the National Cancer Data Base, found that 59% of women who received pre-surgery chemotherapy had breast conservation therapy. Women with larger tumors were also more likely to opt for pre-surgery chemotherapy and lumpectomy versus mastectomy.
A common antibiotic, clarithromycin, has shown potential as an anti-cancer agent when used in combination with other drugs. Low- and middle-income countries may play a key role in developing this treatment, which could lead to improved patient outcomes.
A small prospective study found no significant difference in treatment outcomes between patients with AR-V7-positive and -negative metastatic castration-resistant prostate cancer who received taxane chemotherapy. PSA responses were achieved in 41% of both groups.
A new type of self-healing hydrogel has been developed by MIT chemical engineers that can carry one or two drugs at a time. The gel consists of a mesh network made of nanoparticles and polymers that can be injected through a syringe and released over several days, targeting specific tissues and allowing for long-term drug delivery.
A study published in JAMA Oncology found that at least one clinically relevant genomic alteration was present in most samples tested, suggesting a potential for personalized therapy. The research analyzed 200 cancer of unknown primary site (CUP) samples and identified 169 specimens with potentially targetable genomic alterations.
Researchers from Brigham and Women's Hospital discovered that targeting cancer cells immediately after chemotherapy can make them more vulnerable to treatment. The 'one-two punch' approach involves administering two drugs simultaneously or sequentially, increasing the effectiveness of cancer therapy.
Two major studies strengthen the case for abiraterone as a treatment option for men with advanced prostate cancer. The trials found that receiving abiraterone before chemotherapy significantly extended men's lives by an average of four months, compared to those who did not receive it.
G1 Therapeutics, a UNC-Chapel Hill spinout, has secured $33 million in Series B funding to accelerate clinical development of its lead CDK4/6 inhibitor for cancer treatment. The company aims to develop more effective and less toxic methods to treat patients with cancer.
Research suggests that immuosuppressives and anti-cancer drugs can reanimate hepatitis B in previously infected individuals, according to a study published in Hepatology. The study authors emphasize the importance of routine screening for HBV before starting treatment with immunosuppressives or anti-cancer drugs.
Researchers have developed a new technique called iontophoresis that delivers high concentrations of chemotherapy directly to tumors, reducing the risk of damaging healthy tissue. This technology has the potential to improve treatment outcomes for cancer patients by allowing for more potent anti-cancer drugs to be used.
Researchers discovered a new way to shrink ovarian cancer tumors by inhibiting abnormal angiogenesis. Using a naturally occurring protein inhibitor called 3TSR, the approach improved chemotherapy drug delivery and resulted in significant tumor regression and survival.
A new study published in Journal of Clinical Oncology finds that ultrasound can help surgeons decide whether to remove only a few or all underarm lymph nodes from breast cancer patients who have received chemotherapy, reducing the risk of complications and saving healthcare costs.
A study found that multiplexed genetic screening for EGFR and ALK gene rearrangements followed by molecularly-guided treatment is cost-effective compared to standard chemotherapy. The approach offers better outcomes in terms of quality-adjusted life years gained and life-years, making it a valuable option for patients with NSCLC.
A recent study by OIST researchers used chemogenetic inhibition to suppress neuronal activity in zebra finches, showing that the arcopallium region controls song composition but not order or timing. This precise technique provides a detailed understanding of how unique neurons coordinate vocalization.
Researchers found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The study demonstrates the use of nanotechnology to repurpose existing chemotherapy drugs as effective agents against chemoresistant cancer stem cells.
Researchers found that endothelial cells, the cells lining blood vessels, play a more active role in tumor growth than previously thought. A combination therapy involving anti-Angiopoietin-2 and metronomic chemotherapy showed promising results in reducing metastatic growth and improving survival rates in mice.
A study found that entecavir significantly reduced the incidence of hepatitis B virus (HBV)-related hepatitis and HBV reactivation among patients receiving rituximab-based chemotherapy. The rates were lower in the entecavir group compared to the lamivudine group, with significant reductions in HBV-related complications.
Researchers developed a fast and accurate method for screening cancer drugs using gold nanoparticles, allowing for rapid profiling of various anti-cancer drugs and their mechanisms. This new sensor system uses three-channel detection to identify specific cell death mechanisms, enabling the determination of drug mechanisms in minutes.
Research shows adding chemotherapy drug carboplatin or blood vessel-targeting drug bevacizumab to standard preoperative chemotherapy increases pathologic complete response rates for women with basal-like triple-negative breast cancer. The drugs also showed benefits in certain gene signatures associated with aggressive disease.
Researchers identified increased risk of jaw bone disease in patients taking osteoporosis medications, anticancer drugs, or glucocorticoids. Prevention strategies include good oral hygiene, antibiotics, and surgical treatments to protect at-risk individuals.
Researchers identified two compounds that inhibit mitochondrial energy enzyme MDH2, blocking cardiac damage caused by doxorubicin and reducing heart failure risk. The findings suggest that these compounds could improve cancer treatment outcomes while minimizing cardiac toxicity.
Researchers found that trastuzumab benefits HER2-positive breast cancer patients do not depend on the number of tumor-infiltrating lymphocytes (S-TILs) in their tumors. The study, which measured S-TILs at diagnosis in over 1,000 patients, showed improved recurrence-free survival when chemotherapy alone was used.
Researchers identified two subtypes of breast cancer, Epi-Basal and Epi-Luminal B, which differ in their epigenetic patterns. The subtype Epi-Luminal B is associated with reduced survival rates and requires adjuvant chemotherapy.
Market-access agreements for anti-cancer drugs lack transparency, leading to higher prices for patients in small and low-income countries. The financial arrangements between pharmaceutical manufacturers and health systems are kept confidential, making it difficult for these countries to negotiate lower prices.
A team of researchers has discovered a way to make triple-negative breast cancer cells susceptible to chemotherapy by inhibiting the HIF protein network. The study found that HIF inhibitors can decrease tumor size and prevent relapse in mice, offering new hope for treatment-resistant patients.
Researchers have discovered novel combinations of targeted therapies and chemotherapy regimens that improve survival outcomes for patients with historically poor-prognosis leukemia. These findings, presented at the American Society of Hematology Annual Meeting, offer new hope for elderly and aggressive genetic mutation patients.
A late-stage clinical trial demonstrated that brentuximab vedotin can improve progression-free survival and overall survival in patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplant. The study showed a 20% improvement in progression-free survival rate and high response rates among patients.
Researchers have developed a novel approach to drug screening that could more precisely tailor chemotherapy to a patient's individual blood cancer type. By correcting for the matrix effect, Shin and Mooney believe their approach could identify a subset of drugs that will be more likely to be effective against chronic myeloid leukemias.
Researchers have developed a new technique to wrap chemotherapy drugs in fatty covers called liposomes, reducing heart damage and improving cardiac function. The study found that the group receiving Myocet had better diastolic and systolic function compared to conventional doxorubicin, with less fibrosis development.
A recent study published in the New England Journal of Medicine found that crizotinib significantly improves symptoms and delays cancer growth in patients with ALK-positive non-small cell lung cancer. The trial involved 343 previously untreated patients, showing promising results without unexpected side effects.